MACS: mild by definition, challenging by nature
- 1Department of Internal Medicine and Endocrinology, Medical University of Warsaw
- 2Doctoral School of the Medical University of Warsaw
- 3Student Scientific Club “Endocrinus” Affiliated to the Department of Internal Medicine and Endocrinology, Medical University of Warsaw
Abstract
Mild autonomous cortisol secretion (MACS) is the most frequent form of cortisol excess in patients with adrenal incidentalomas. Although it lacks the classical phenotype of overt Cushing’s syndrome, MACS is increasingly recognized as a clinically relevant condition associated with multisystem complications rather than a benign biochemical finding. This narrative review summarizes current evidence on the pathophysiology, clinical manifestations, diagnostic limitations, and management of MACS, with particular focus on cardiometabolic, skeletal, muscular, neuropsychiatric, frailty-related, reproductive, and emerging microbiome-related consequences. Chronic exposure to low-grade cortisol excess is being recognized as a factor associated with hypertension, disorders of glucose metabolism, dyslipidemia, increased cardiovascular risk, metabolic dysfunction-associated steatotic liver disease, skeletal fragility, impaired muscle function, frailty, sleep and circadian disturbances, cognitive and mood alterations, hypogonadism, and possible changes in gut microbiota. The 1 mg overnight dexamethasone suppression test remains the cornerstone of diagnosis, but its interpretation is limited by assay variability, medication interference, comorbidities, and imperfect reflection of long-term tissue glucocorticoid exposure. Emerging approaches, including steroid profiling, hair cortisol/cortisone, salivary cortisone, inflammatory indices, metabolomic tools, and exploratory biomarkers related to microbial metabolites, may improve risk stratification in the future but remain investigational. Management should be individualized. Adrenalectomy may benefit selected patients with unilateral disease and clinically relevant cortisol-related comorbidities, whereas evidence supporting pharmacological therapy remains limited. MACS should be regarded as a heterogeneous multisystem condition requiring structured clinical assessment and individualized management. Prospective studies are needed to define clinically meaningful endpoints, refine diagnostic thresholds, and identify patients most likely to benefit from intervention.
Related
- Prevalence and predictors of abnormal cervical cytology among women living with HIV and without HIV from the MACS/WIHS combined cohort study
- Bridging Experience and New Frontiers in Left Ventricular Assist Device Therapy in Japan ― Insights From the J-MACS Report ―
- Nationwide Evolution of Durable Left Ventricular Assist Device Outcomes Following Introduction of the HeartMate 3 and Destination Therapy in Japan ― The Third Official Report From J-MACS ―
- Feasibility of steerable sheath-guided left atrial appendage closure in challenging anatomy
- Challenging case of leadless pacemaker implantation for a patient with left-sided inferior vena cava.
BibTeX
@article{bluszcz2026macs,
title = {{MACS: mild by definition, challenging by nature}},
author = {Gabriela Bluszcz and Zuzanna Roszkowska and Jan Domański and Ahmad Sharabi and Joanna Rapiejko and Jerzy Małek and Urszula Ambroziak and Małgorzata Bobrowicz},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1957127},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1957127/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - MACS: mild by definition, challenging by nature
AU - Gabriela Bluszcz
AU - Zuzanna Roszkowska
AU - Jan Domański
AU - Ahmad Sharabi
AU - Joanna Rapiejko
AU - Jerzy Małek
AU - Urszula Ambroziak
AU - Małgorzata Bobrowicz
PY - 2026
DA - 2026/10/26
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1957127
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1957127/full
AB - Mild autonomous cortisol secretion (MACS) is the most frequent form of cortisol excess in patients with adrenal incidentalomas. Although it lacks the classical phenotype of overt Cushing’s syndrome, MACS is increasingly recognized as a clinically relevant condition associated with multisystem complications rather than a benign biochemical finding. This narrative review summarizes current evidence on the pathophysiology, clinical manifestations, diagnostic limitations, and management of MACS, with particular focus on cardiometabolic, skeletal, muscular, neuropsychiatric, frailty-related, reproductive, and emerging microbiome-related consequences. Chronic exposure to low-grade cortisol excess is being recognized as a factor associated with hypertension, disorders of glucose metabolism, dyslipidemia, increased cardiovascular risk, metabolic dysfunction-associated steatotic liver disease, skeletal fragility, impaired muscle function, frailty, sleep and circadian disturbances, cognitive and mood alterations, hypogonadism, and possible changes in gut microbiota. The 1 mg overnight dexamethasone suppression test remains the cornerstone of diagnosis, but its interpretation is limited by assay variability, medication interference, comorbidities, and imperfect reflection of long-term tissue glucocorticoid exposure. Emerging approaches, including steroid profiling, hair cortisol/cortisone, salivary cortisone, inflammatory indices, metabolomic tools, and exploratory biomarkers related to microbial metabolites, may improve risk stratification in the future but remain investigational. Management should be individualized. Adrenalectomy may benefit selected patients with unilateral disease and clinically relevant cortisol-related comorbidities, whereas evidence supporting pharmacological therapy remains limited. MACS should be regarded as a heterogeneous multisystem condition requiring structured clinical assessment and individualized management. Prospective studies are needed to define clinically meaningful endpoints, refine diagnostic thresholds, and identify patients most likely to benefit from intervention.
SN - 1664-2392
ER -